Abstract 107P
Background
Hepatocellular carcinoma (HCC), which comprises the majority of liver cancer was a leading cause of death worldwide. The high rate of recurrence severely hampers the long-term survival of HCC patients after hepatectomy. Early recurrence, which is mainly caused by intrahepatic dissemination, accounts for nearly 70% of all recurrent cases. Circulating tumor cells (CTC) has shown potential clinical implications. CTC was associated with the severity of microvascular invasion (mVI) in the peritumoral tissue. Patients with positive CTC have higher risk of recurrence, associate with poorer survival. However, it remains unclear whether CTC is helpful in guiding the surgical plan.
Methods
In this perspective design, retrospective study, we enrolled 60 eligible patients with resectable HCC, and Child-Pugh A liver function, preoperative CTC detection was positive between January 2021 and May 2022. Thirty patients underwent anatomical resection (AR) and 30 patients underwent non-anatomical resection (NAR), clinical outcomes including clinicopathologic characteristics, recurrence-free survival (RFS) were compared.
Results
There was no significant difference in the preoperative data and incidence of blood loss and transfusion requirements between the AR group and the NAR group, although wedge resection was mainly performed in the NAR group. No major complications occurred in either group. All patients achieved radical resection, and 25 patients (41.7%, 25/60) were mVI-positive in the pathological detection. There were17 mVI-positive in the AR group and 8 mVI-positive in the NAR group. During follow-up, recurrence was more frequent in patients treated with NAR, there was 8 (26.6%) recurrence in the NAR group and 3 (10%) recurrence in the AR group. The 1-year RFS in AR and NAR groups were 90% and 73.3% (p<0.05). Multivariate analysis showed the type of surgical treatment was an independent predictor of disease recurrence.
Conclusions
In conclusion, preoperative CTC status correlated with and predicted mVI in HCC patients. AR should be performed in CTC positive in preoperative patients for ensuring disease eradication. Based on the preliminary results, randomized controlled trials will be conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research supported by Sanming Project of Medicine in Shenzhen (No.SZSM202011010).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02